QNTM Quantum Biopharma Ltd.
NEUTRAL
Impact: 3/10
6-K
Notable filing: 6-K
Price Chart
Loading chart...
Executive Summary
Quantum BioPharma engaged Stocks.news/IR Agency LLC for investor relations and marketing services for 6 months at a $250,000 fee. The filing is a routine service agreement with no financial or operational data, and no material impact on the company's fundamentals or pipeline.
Actionable Insight
This is a routine IR engagement with no immediate catalyst. Monitor for future pipeline updates or financial disclosures that could move the stock.
Key Facts
- Quantum BioPharma entered an IR and consulting agreement with Stocks.news via IR Agency LLC starting June 8, 2026.
- The agreement is for 6 months at a fee of US$250,000.
- The Agency and its principals hold no equity interest in Quantum's securities.
- Rafael Pereira will provide the investor relations services.
- No financial results, pipeline updates, or operational changes were disclosed.
Financial Impact
US$250,000 fee for 6 months of IR services; no revenue or earnings impact disclosed.
Risk Factors
- The $250,000 fee is a cash expense for a company with a $34M market cap, but no material financial impact is indicated.
- No guarantee that the IR campaign will increase investor awareness or share price.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003862 |
| Document: f6k_060226.htm | 0001171843-26-003862 |
| Document: 0001171843-26-003862-index-headers.html | 0001171843-26-003862 |
| Document: 0001171843-26-003862.txt | 0001171843-26-003862 |
15 reports for QNTM
80%
Hit rate
best @ T+1▲ +52.58%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
4d ago
|
6-K
| $5.11 $4.88 | ▲ +4.50% | ▲ +3.81% | $4.26 (+16.63%) |
|
Jun 2, 2026
4d ago
|
6-K
| — | awaiting T+1 | — | — |
|
May 18, 2026
19d ago
|
6-K
| — | awaiting T+1 | — | — |
|
Apr 22, 2026
6w ago
|
6-K
| $3.35 $3.21 | ▼ −4.18% | ▼ −3.79% | $4.26 (+27.16%) |
|
Apr 22, 2026
6w ago
|
Press Release
| $3.35 $3.21 | ▼ −4.18% | ▼ −3.79% | $4.26 (+27.16%) |
|
Apr 2, 2026
9w ago
|
6-K
| $3.98 $3.58 | ▼ −10.05% | ▼ −10.53% | $4.26 (+7.04%) |
|
Apr 1, 2026
9w ago
|
6-K
| $4.41 $3.98 | ▼ −9.75% | ▼ −9.83% | $4.26 (−3.40%) |
|
Apr 1, 2026
9w ago
|
Press Release
| $4.41 $3.98 | ▼ −9.75% | ▼ −9.83% | $4.26 (−3.40%) |
|
Mar 30, 2026
9w ago
|
Court Ruling
| $4.28 $4.83 | ▲ +12.85% | ▲ +9.96% | $4.26 (−0.47%) |
|
Mar 27, 2026
10w ago
|
6-K
| $4.77 $4.28 | ▼ −10.27% | ▼ −9.91% | $4.26 (−10.69%) |
Showing 10 of 15
US Market Status
Market Closed — Opens Mon (14h 55m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access